WSD0922-FU is named as an intervention in 3 current clinical trials in our China and USA registers. 3 are recruiting patients now. The most common phase is Phase 1/2. The lead sponsor is Wayshine Biopharm, Inc. The most-studied condition is Non Small Cell Lung Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
NCT06868485 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
|
Phase 2 | Recruiting | Wayshine Biopharm, Inc. | USA, China |
|
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
NCT06631989 · ClinicalTrials.gov ↗ · EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
|
Phase 1/2 | Recruiting | Wayshine Biopharm, Inc. | China |
|
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
NCT07206498 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer (NSCLC)
|
Phase 1/2 | Recruiting | Wayshine Biopharm, Inc. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Wayshine Biopharm, Inc. | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 3 |
| Clinical trials in USA | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China and USA registers name WSD0922-FU (also registered as WSD0922) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 3 trials are recruiting: 3 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Wayshine Biopharm, Inc. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how WSD0922-FU works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how WSD0922-FU works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists WSD0922-FU (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.